[1] 祝训浩, 刘蔚, 王乾昌,等. 原发性肝癌转化治疗研究进展及展望[J]. 临床医学进展, 2022, 12(12):11680-11685. [2] Khatib SA, Xin WW. Causes and functional intricacies of inter- and intratumor heterogeneity of primary liver cancers[J]. Adv Cancer Res, 2022, 156:75-102. [3] Li Z, Kwon SM, Li D, et al.Human constitutive androstane receptor represses liver cancer development and hepatoma cell proliferation by inhibiting erythropoietin signaling[J]. J Biol Chem, 2022,298(5):298. [4] Zhang G, Peng Z, Yan C, et al.A novel liver cancer diagnosis method based on patient similarity network and DenseGCN[J]. Sci Rep, 2022, 12(1):6797. [5] Kubota N, Fujiwara N, Hoshida Y. Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts[J]. Adv Cancer Res, 2022, 156:1-37. [6] Lu L L, Zhang YH, Yao MH, et al.ABO blood groups and liver cancer: Prospective results from an HBsAg cohort study[J]. BMJ Open, 2021, 11(5):e044039. [7] Romano F, Chiarelli M, Garancini M, et al.Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery?[J]. World J Gastroenterol, 2021, 27(21):2784-2794. [8] 黄灿坡, 黄进发, 王琳,等. 预防性TACE对合并微血管浸润的肝癌患者术后复发,生存率的影响[J]. 湖南师范大学学报(医学版), 2021,18(6):189-192. [9] 张猛, 李耀光, 王科妍,等. 肿瘤相关抗原自身抗体用于慢性乙型肝炎相关肝硬化人群肝癌筛查的成本效果分析[J]. 中华医学杂志, 2021, 101(32):2544-2551. [10] Hackshaw A, Clarke CA, Hartman AR. New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening[J]. Cancer Cell, 2022, 40(2):109-113. [11] Tseng TC, Hosaka T, Liu CJ, et al.Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase[J]. Am J Gastroenterol, 2022,117(5):748-757. [12] Soulen MC, García-Mónaco R. Closing the gap in curative ablation of liver cancer[J]. Radiology, 2021,301(1):237-238. [13] 安仙园, 袁丹丹, 徐忆秋,等. 血浆游离双链DNA在原发性肝癌中的诊断价值[J]. 江苏大学学报:医学版, 2021, 31(3):46-250. [14] 刘斌, 孙君, 陈枫,等. 临床影像综合模型在透明细胞型肝癌精准诊断中的价值[J]. 中国医学影像学杂志, 2021, 29(9):897-901. [15] Bruix J. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot[J]. J Hepatol, 2021, 74(6):1483-1488. [16] Nguyen A, Blizzard CL, Yee KC, et al.Survival of primary liver cancer for people from culturally and linguistically diverse backgrounds in Australia[J]. Cancer Epidemiol, 2022, 81:102252. [17] 于连政. 2016—2018年沈阳市城市居民肝癌高危风险评估及筛查效果分析[J]. 中国肿瘤, 2021, 30(4):286-291. [18] 师金, 梁迪, 李道娟,等. 中国城市癌症早诊早治项目筛查依从性及影响因素研究[J]. 中国肿瘤, 2021, 30(8):591-599. [19] 曹毛毛, 李江, 孙殿钦,等. 全球肝癌筛查指南及共识质量评价[J]. 中华流行病学杂志, 2021, 42(2):234-240. [20] Kimanya ME, Routledge MN, Mpolya E, et al.Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data[J]. PLoS One, 2021, 16(3):e0247281. [21] 马佳敏, 刘双, 张梦伟. 枸杞多糖联合有氧运动对非酒精性脂肪肝大鼠的保护作用[J]. 宁夏医科大学学报, 2021, 43(5):439-446. [22] Bai Y, Pei W, Zhang X, et al.ApoM is an important potential protective factor in the pathogenesis of primary liver cancer[J]. J Cancer, 2021, 12(15):4661-4671. [23] 尚学敏, 何爽, 王静. 郑州地区健康体检者肝癌高危筛查结果分析[J]. 华南预防医学, 2022,48(7):864-866,870. [24] 郝新, 樊蓉, 侯金林. 原发性肝癌高危人群的早期预警和精准筛查[J]. 临床肝胆病杂志, 2022, 38(3):499-504. [25] 郭兰伟, 张韶凯, 刘曙正,等. 河南省城市地区肝癌筛查依从性及其影响因素分析[J]. 中华肿瘤杂志, 2021, 43(2):233-237. |